Natco Pharma Limited — Sorafenib Exporter Profile
Indian Pharmaceutical Exporter · #2 for Sorafenib · $850.0K export value · DGFT Verified
Natco Pharma Limited is the #2 Indian exporter of Sorafenib with $850.0K in export value and 17 verified shipments. Natco Pharma Limited holds a 5.1% market share in Sorafenib exports across 4 countries. The company exports 17 pharmaceutical products worth $36.0M across 6 therapeutic categories.
Natco Pharma Limited — Sorafenib Export Profile: Buyers & Destinations

Where Does Natco Pharma Limited Export Sorafenib?
| Country | Value | Shipments | Share |
|---|---|---|---|
| THAILAND | $150.0K | 3 | 55.6% |
| SAUDI ARABIA | $50.0K | 1 | 18.5% |
| FRANCE | $50.0K | 1 | 18.5% |
| NEPAL | $19.9K | 12 | 7.4% |
Natco Pharma Limited exports Sorafenib to 4 countries. The largest destination is THAILAND accounting for 55.6% of Natco Pharma Limited's Sorafenib shipments, followed by SAUDI ARABIA (18.5%) and FRANCE (18.5%). These destinations reflect Natco Pharma Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Sorafenib from Natco Pharma Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ATLANTA MEDICARE CO LTD | THAILAND | $100.0K | 2 |
| ATLANTA MEDICARE CO. LTD | THAILAND | $50.0K | 1 |
| BOSTON ONCOLOGY ARABIA | SAUDI ARABIA | $50.0K | 1 |
| SOPHAL SPA | FRANCE | $50.0K | 1 |
| EVEREST BANK LTD | NEPAL | $11.7K | 7 |
| EVEREST BANK LIMITED | NEPAL | $5.8K | 3 |
| EVEREST BANK LTD. | NEPAL | $2.3K | 2 |
Natco Pharma Limited supplies Sorafenib to 7 buyers globally. The largest buyer is ATLANTA MEDICARE CO LTD (THAILAND), followed by ATLANTA MEDICARE CO. LTD (THAILAND) and BOSTON ONCOLOGY ARABIA (SAUDI ARABIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Sorafenib Export Value and How Much Does Natco Pharma Limited Contribute?
India exported $1.9M worth of Sorafenib through 916 shipments from 203 suppliers to 98 countries, serving 341 buyers globally. Natco Pharma Limited contributes $850.0K to this total, accounting for 5.1% of India's Sorafenib exports. Natco Pharma Limited ships Sorafenib to 4 countries through 7 buyers.
What Is the Average Shipment Value for Natco Pharma Limited's Sorafenib Exports?
Natco Pharma Limited's average Sorafenib shipment value is $50.0K per consignment, based on 17 shipments totaling $850.0K. The largest destination is THAILAND (55.6% of Natco Pharma Limited's Sorafenib exports).
How Does Natco Pharma Limited Compare to Other Indian Sorafenib Exporters?
Natco Pharma Limited ranks #2 among 203 Indian Sorafenib exporters with a 5.1% market share. The top 3 exporters are NATCO PHARMA LIMITED ($850.0K), TORRENT PHARMACEUTICALS LTD ($600.0K), MEDYRA PHARMACEUTICAL ($162.4K). Natco Pharma Limited processed 17 shipments to 4 destination countries.
What Sorafenib Formulations Does Natco Pharma Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| SORAFENAT 200MG TABLETS 60'S(SORAFENIB T | $50.0K | 1 |
| SORAFENAT 200MG TABLETS 60'S SORAFENIBTOSYLATE1706X60'SAPPENDIX 4R,RODTEPENTRY NO:10112OTHERREFSCI NO:123164 | $50.0K | 1 |
| SORAFENIB 200MG TABLETS (APPENDIX 4R RODTEP ENTRY NO: 10112 (OTHER REF CI NO:124049) | $50.0K | 1 |
| SORAFENIB 200MG TABLETS (SORAPHAL 200MG) (1280X100'S) (APPENDIX 4R RODTEP ENTRY NO.10112) (OUR REF INV NO.124268) | $50.0K | 1 |
| SORAFENAT 200MG TABLETS 60 S SORAFENIB TOSYLATE 1550X60 S APPENDIX 4R RODTEPENTRY NO 10112 OUR REF S CI NO125043 | $50.0K | 1 |
| SORAFENAT 120'S PER BOTTLE (SORAFENIB TABLETS 200MG)(75X120'S)(APPENDIX4R,RODTEP ENTRYNO:10112) | $5.0K | 1 |
| SORAFENAT 200MG TAB 120'S(SORAFENIB TABLETS)(50X120'S)(APPENDIX4R,RODTEPENTRY NO:10112)(OTHERREF(S)CINO:CWH-2023-017)NOS | $3.6K | 1 |
| SORAFENAT 120 S PER BOTTLE SORAFENIB TABLETS 200MG 50X120 S APPENDIX4R RODTEPENTRYNO 10112 | $3.4K | 1 |
| SORAFENAT 200MG TABLETS 120'S (SORAFENIB200MG)(25X120'S)(APPENDIX4RRODTEPENTRYNO:10112) | $1.8K | 1 |
| SORAFENAT 200MG TABLETS 120'S (SORAFENIB200MG)(20X120'S)(APPENDIX4R,RODTEP ENTRYNO:10112) | $1.4K | 1 |
Natco Pharma Limited exports 17 distinct Sorafenib formulations including tablets, capsules, syrups, and combination drugs. The top formulation is SORAFENAT 200MG TABLETS 60'S(SORAFENIB T with 1 shipments worth $50.0K.
How Does Natco Pharma Limited Compare to Nearest Sorafenib Exporters?
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | NATCO PHARMA LIMITED ★ | $850.0K | 17 | 4 | $50.0K |
| 1 | TORRENT PHARMACEUTICALS LTD | $600.0K | 12 | 2 | $50.0K |
| 3 | MEDYRA PHARMACEUTICAL | $162.4K | 15 | 4 | $10.8K |
Natco Pharma Limited ranks #2 among 203 Indian Sorafenib exporters. Average shipment value of $50.0K compared to the market average of $9.3K. The closest competitors by value are TORRENT PHARMACEUTICALS LTD and MEDYRA PHARMACEUTICAL.
Which Indian Ports Ship Sorafenib Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 245 | 26.7% |
| SAHAR AIR | 197 | 21.5% |
| DELHI AIR CARGO ACC (INDEL4) | 89 | 9.7% |
| Bombay Air | 69 | 7.5% |
| DELHI AIR | 68 | 7.4% |
| AHEMDABAD AIR | 37 | 4.0% |
| Bombay Air Cargo | 27 | 2.9% |
| AHEMDABAD AIR ACC (INAMD4) | 20 | 2.2% |
What Other Advanced Oncology Products Does Natco Pharma Limited Export?
Natco Pharma Limited also exports these advanced oncology products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Natco Pharma Limited's Sorafenib Exports
Natco's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly impactful for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management. (pharmaceuticalcommerce.com)
In the United States, recent tariff implementations have introduced additional complexities for Indian pharmaceutical exporters. The U.S. administration's imposition of tariffs on imports from various countries, including India, has raised concerns about the competitiveness of Indian generics in the U.S. market. These tariffs could potentially erode profit margins and affect pricing strategies. (apnews.com)
Conversely, the European Union's stringent regulatory changes, such as the Falsified Medicines Directive, have heightened compliance requirements for exporters. While these regulations aim to ensure product authenticity and safety, they also necessitate significant investments in serialization and traceability systems. For companies like Natco, adhering to these standards is crucial for maintaining access to the lucrative EU market.
Natco Pharma Limited — Regulatory Compliance & Quality Standards
The global pharmaceutical industry is witnessing intensified scrutiny regarding quality and compliance. The U.S. Food and Drug Administration (FDA) has increased inspections of Indian manufacturing facilities, emphasizing adherence to Good Manufacturing Practices (GMP). Non-compliance can lead to warning letters, import alerts, or even bans, posing significant risks to exporters. (fact.net.in)
Natco's commitment to quality is evident in its proactive measures to meet international standards. The company's recent product approvals and successful market entries suggest a robust compliance framework. However, continuous vigilance and investment in quality systems are imperative to navigate the evolving regulatory landscape and to sustain export growth.
About Natco Pharma Limited
Natco Pharma Limited exports 17 products worth $36.0M. Beyond Sorafenib, top products include Everolimus, Oseltamivir, Apixaban, Anastrozole, Ondansetron. View the complete Natco Pharma Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Sorafenib — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Sorafenib shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Natco Pharma Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 17 individual customs records matching Natco Pharma Limited exporting Sorafenib, covering 17 formulations to 4 countries via 7 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 98+ countries, 341+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Sorafenib Export Data from Natco Pharma Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Natco Pharma Limited's Sorafenib exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Natco Pharma Limited
Full Company Profile →
17 products · $36.0M total trade · 6 categories
Sorafenib Stats
Company Overview
Top Products by Natco Pharma Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Natco Pharma Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Sorafenib. For current shipment-level data, contact TransData Nexus.